News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr Julie Cherrington Joins Xenome Ltd Board


8/11/2009 12:07:26 PM

Brisbane, Australia. 11 August 2009: Xenome Limited (“Xenome”) today announced that Dr Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director. Dr Cherrington is President of Phenomix Corporation, a San Diego based biopharmaceutical company focused on the development and commercialisation of drugs for the treatment of metabolic and infectious diseases. Prior to her appointment as President, Dr Cherrington served as the Executive Vice President of Research and Development at Phenomix. Before joining Phenomix, Dr Cherrrington held senior research positions at prominent biotechnology companies such as SUGEN, Inc. and Gilead Sciences, Inc.

Recently Dr Cherrington joined the Board of ASX and NASDAQ listed Progen Pharmaceuticals Limited. She has also served on the Board of ChemGenex Pharmaceuticals Limited.

Xenome’s Chairman, Mr Jim Hazel, welcomed Dr Cherrington’s appointment as an important step in the ongoing evolution of the Xenome Board. “We are delighted to have a person of Julie’s stature and experience join the Board and look forward to her help in building Xenome as a drug development company.”

Dr Cherrington’s appointment took effect on 1 August 2009.

About Xenome:

Xenome is a biotechnology company focused on the discovery and development of peptidebased therapeutics. Utilising its expertise in peptide chemistry and its novel technology platform, Xenome translates the evolutionary advantages inherent in venom peptides into new drug candidates.

The Company's lead product, Xen2174, is a novel conopeptide analogue for the treatment of moderate to severe pain. Xen2174 is a non-competitive inhibitor of norepinephrine transporter (NET), a validated target for the management of pain. In an international phase I/II clinical trial in cancer patients, a single intrathecal administration of Xen2174 was found to be safe and well-tolerated across a broad dose range. In addition, the study provided evidence for an analgesic effect that had a rapid onset of action and was longlasting. Xenome's discovery platform is based on proprietary libraries of venom peptides, analogues and mimetics. Research license agreements are in place with Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and MedImmune LLC (a wholly-owned subsidiary of AstraZeneca), each of which have access to Xenome’s xdiscoverTM library for specific indications or targets.

Further information can be obtained from the Xenome website (www.xenome.com).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES